Ms. Jenna McNeil reports

APPILI THERAPEUTICS ANNOUNCES FORMAL TERMINATION OF ARRANGEMENT AGREEMENT WITH ADITXT INC.

In response to the notice received from Aditxt Inc. on May 17, 2025, Appili Therapeutics Inc. has delivered formal notice to Aditxt to terminate the arrangement agreement dated April 1, 2024 (as amended), between the company, Aditxt and its wholly owned subsidiary, Adivir Inc. Such termination is effective as of May 30, 2025.

Under the arrangement agreement, the company is entitled to a termination fee in the amount of $1.25-million (U.S.) payable by Aditxt. This termination fee has been reduced by certain amounts previously paid to the company by Aditxt to extend the outside date under the arrangement agreement. As of the date hereof, the amount of $1-million (U.S.) remains payable to Appili on account of the termination fee.

Lender extensions

In connection with the termination of the arrangement agreement, Appili has secured three-month extensions to the amounts due under each of (1) the amended and restated secured loan agreement with Long Zone Holdings Inc. (the LZH loan), and (2) the unsecured promissory notes with Bloom Burton & Co. Inc. Pursuant to the terms of such extensions, all amounts owing under the LZH loan and the Bloom Burton loan, together with all accrued and unpaid interest, will be due on Aug. 31, 2025.

About Appili Therapeutics Inc.

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio driven and people focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili's goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The company is currently advancing a diverse range of anti-infectives, including an Food and Drug Administration-approved ready-made suspension of metronidazole for the treatment of antimicrobial resistant infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicentre of the global fight against infection.

We seek Safe Harbor.